Key points are not available for this paper at this time.
Chlamydia trachomatis (C. t) is the most common causative agent of sexually transmitted bacterial urogenital infections worldwide. C. t treatment failure is increasing because antibiotic resistance has developed in recent years. Therefore, the development of novel therapeutic strategies is necessary. Here, we constructed an M13 phage carrying two functional peptides, including the integrin binding peptide arginine-glycine-aspartic acid (RGD) on pⅧ and the IN5 protein from Chlamydia caviae phage φCPG1 on pIII to reduce C. t infection. We called these phages M13-RGD 8 -IN5 3. The recombinant phages successfully expressed IN5 proteins. Confocal laser scanning microscopy confirmed that the recombinant phages were able to enter HeLa cells and C. t inclusion bodies. IN5 protein was responsible for the observed decrease in C. t infection, while RGD enhanced the permeability of phages into the cells. The M13-RGD 8 -IN5 3 phage was better than the M13-IN5 3 phage in ameliorating C. t infection. qPCR revealed that treatment with the recombinant phages downregulated several C. t genes related to virulence, such as CT₀46 (Hc2), CT₄43 (OmcB), CT₄44 (OmcA), CT₄56 (Tarp), CT₆66 (Cdsf), CT₆94, CT₇43 (Hc1), and CT₈75 (TepP). The only upregulated gene was CT₁19 (IncA). The recombinant phages impacted the C. t mainly in the middle and late stages of the development cycle. Our results suggest that novel recombinant phages are promising as candidates to treat C. t infection.
You et al. (Sat,) studied this question.